Supporting this hypothesis, all samples belonging to high CYT score in the tumor inflammation signature (TIS) score were reported to be correlated with a response to anti PD-L1 checkpoint inhibitor pembrolizumab (p < 0.0001, Figure 8(a)). Here, CD274 is linked to neoplasm.